Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

NCT00932646 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: BI 1744 (Olodaterol) Low Dose
DRUG: BI 1744 (Olodaterol) Medium Dose
DRUG: Placebo
DRUG: Foradil

Sponsor

Boehringer Ingelheim